Real-world Drug Survival of Guselkumab in Patients With Psoriasis Stratified by Weight and Comorbidities: Retrospective, Observational Data From the British Association of Dermatologists Biologics and Immunomodulators Register

Clicks: 23
ID: 327796
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #82 of 245 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 245 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In the United Kingdom (UK), 89.1% of patients with moderate-to-severe psoriasis are overweight or obese, and 53.2% have at least one comorbidity. However, real-world data on biologic-treated patients with psoriasis and comorbidities remains limited. Objectives were to compare 36-month drug survival of guselkumab in patients across weight and body mass index (BMI) categories, and in those with or without specific comorbidities. This retrospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), collected from January 2018 to July 2024. Co-primary outcomes were overall drug survival, and drug survival stratified by weight and BMI categories, over 36 months, for guselkumab-treated patients. Secondary outcomes included 36-month drug survival among guselkumab-treated patients with and without specific comorbidities, including but not limited to, metabolic syndrome, hypertension, anxiety and/or depression. Kaplan-Meier methodology was used to estimate probabilities for time-to-treatment discontinuation across all patient groups analysed. Among the 482 participants included in this analysis who initiated guselkumab treatment, 36-month drug survival was generally high, with an overall drug survival rate of 0.75 (95% CI, 0.71-0.79). Stratified by weight, drug survival rates were 0.71 (95% CI, 0.59-0.86) for patients <80 kg, 0.79 (95% CI, 0.71-0.87) for those 80-<90 kg, 0.74 (95% CI, 0.68-0.82) for those 90-<100 kg, and 0.74 (95% CI, 0.66-0.82) for those ≥100 kg. Drug survival by BMI category was 0.78 (95% CI, 0.71-0.86) for patients <30 kg/m2 and 0.73 (95% CI, 0.69-0.79) for those ≥30 kg/m2. Across all comorbidities analysed, drug survival at 36 months remained ≥0.69, with no significant differences observed in patients with comorbidities compared to those without. In this UK real-world analysis, drug survival rates for guselkumab over 36 months were consistent across patients with psoriasis in different weight and BMI categories, and were not adversely affected by the presence of comorbidities. This analysis has limitations due to the high proportion of missing weight and BMI data at baseline. Nonetheless, these findings support guselkumab use as a durable treatment option in routine practice, for patients with obesity and other common comorbidities.
Reference Key
openalex_W7211934506 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laura Savage, Maria-Angeliki Gkini, Xiayi Wang, Louise Topping, Bhavika Chauhan
Are you one of these authors? Claim your profile
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag363
URL
https://doi.org/10.1093/ced/llag363
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.